IL2 and hereditary clear cell renal cell carcinoma: Immunotherapy drugs used in the treatment of renal cell carcinoma in China include nivolumab, pembrolizumab, interleukin 2 and recombinant human interferon α2b.For medium to high-risk patients, dual immunotherapy is superior to single targeted therapy [30].